For those with severe alopecia areata, with greater than 50% scalp involvement, topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester is considered the treatment of choice. This article not only reviews the safety and efficacy of topical sensitizers for the treatment of alopecia areata but also highlights strides that have been made in the literature concerning their use in pediatric populations, molecular mechanisms of efficacy, and improved safety through targeted delivery methods.
Get full access to this article
View all access options for this article.
References
1.
HelmF, KleinE, TraenkleHL, et al.Studies on the local administration of 2,3,5-tri-ethylene-imino-1,4,-benzoquinone to epitheliomas. J Invest Derm, 1965; 45: 152–159.
2.
MatterB, SchmidW. Trenimon-induced chromosomal damage in bone-marrow cells of six mammalian species, evaluated by the micronucleus test. Mutat Res, 1971; 12: 417–425.
3.
MitchellAJ, KrullEA. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol, 1984; 11: 763–775.
4.
LewisHM. Topical immunotherapy of refractory warts. Cutis, 1973; 12: 863–867.
5.
OlsenEA, HordinskyMK, PriceVH, et al.Alopecia areata investigational assessment guidelines—Part II. National Alopecia Areata Foundation. J Am Acad Dermatol, 2004; 51 (3): 440–447.
6.
AghaeiS. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol, 2005; 5: 6.
7.
DelamereFM, SladdenMM, DobbinsHM, et al.Interventions for alopecia areata. Cochrane Database Syst Rev, 2008; 2:CD004413.
8.
PascherF, KurtinS, AndradeR. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of ensuing localized acneform response. Dermatologica, 1970; 141 (3): 193–202.
9.
PanJY, ThengC, LeeJ, et al.Vitiligo as an adverse reaction to topical diphencyprone. Ann Acad Med Singapore, 2009; 38 (3): 276–277.
PerrotCM, SteijlenPM, ZaunH, et al.Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy. Contact Dermatitis, 1989; 21 (3): 196–197.
WisemanMC, ShapiroJ, MacDonaldN, et al.Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol, 2001; 137 (8); 1063–1068.
14.
SinghG, LavanyaM. Topical immunotherapy in alopecia areata. Int J Trichology, 2010; 2 (1): 36–39.
15.
HarriesMJ, SunJ, PausR, et al.Management of alopecia areata. BMJ, 2010; 341: c3671.
WilkersonMG, ConnorTH, HenkinJ, et al.Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol, 1987; 17: 606–611.
21.
GulatiN, Suarez-FarninasM, GilleaudeauP, et al.Topical DPCP induces distinct early and late phase cellular immune reactions in human skin. J Invest Dermatol, 2013; 133: S159–S190.
22.
WilkersonMG, HenkinK, WilkinJK, et al.Squaric acid and esters:analysis for contaminants and stability in solvents. J Am Acad Dermatol, 1985; 13: 229–234.
HappleR, EchternachtK, Induction of hair growth in alopecia areata with DNCB. Lancet, 1977; 2: 1002–1003.
25.
MoritaK, NakamuraM, NagamachiM, et al.Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. J Dermatol, 2002; 29: 661–664.
26.
RoksharCK, ShupackJL, VafaiJJ, et al.Efficacy of topical sensitizers in treatment of alopecia areata. J Am Acad Dermatol, 1998; 39: 751–761.
27.
HolzerAM, KaplanLL, LewisWR. Haptens as drugs: contact allergens are powerful topical immunomodulators. J Drugs Dermatol 2006;, 5; 410–416.
28.
HomeyB, AleniusH, MullerA, et al.CCL27-CCR10 interactions regulate T cell medicated skin inflammation. Nat Med, 2002; 8: 157–165.
29.
SimonettiO, LucariniG, BernardiniML, et al.Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol, 2004; 150: 940–948.
30.
PriceVH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol, 1987; 16: 730–736.
31.
GulatiN, Suarez-FarinasM, Fuentes-DuculanJ, et al.Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights. J Invest Dermatol, 2014; 134: 2531–2540.
32.
D’Ovidio RAlopecia areata: news of diagnosis, pathogenesis, and treatment. Ital J Dermatol Venereol, 2014; 149: 25–45.
33.
OrecchiaG, PerfettiL. Alopecia areata and topical sensitizers; allergic response is necessary but irritation is not. Br J Dermatol, 1991; 124 (5): 509.
34.
OchoaBE, SahD, WangG, et al.Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol, 2009; 61 (3): 530–532.
35.
McMichaelAJ, PearceDJ, WassermanD, et al.Alopecia in the United States: outpatient utilization and common prescribing pattern. J Am Acad Dermatol, 2007; 57: S49–S51.
36.
WassermanD, Guzman-SanchezDA, ScottK, et al.Alopecia areata. Int J Dermatol, 2007; 46 (2): 121–123.
37.
GohC, FinkelM, ChristosPJ, et al.Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease, and positive family history. J Eur Acad Dermatol Venereol, 2006; 20 (9): 1055–1060.
38.
TostiA, WhitingD, IorizzoM, et al.The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol, 2008; 59: 64–67.
39.
WesterhofW, NjooD, MenkesHE. Sudden whitening of hair. In: NordlundJJ, BoissyRE, HearingVJ, KingR, OettingW, et al., eds. The Pigmentary System. 2nd ed. Malden, MA: Blackwell; 2006: 764–766.
PausR, SlominskiA, CzarnetzkiBM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb?. Yale J Biol Med, 1993; 66: 541–554.
46.
SiebenhaarF, SharovAA, PetersEM, et al.Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol, 2007; 127: 1489–1497.
47.
PetersEM, LiotiriS, BodóE, et al.Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol, 2007; 171: 1872–1886.
48.
ItoT, ItoN, BettermannA, et al.Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair folicle as a model. Am J Pathol, 2004; 164: 623–634.
49.
ItoT, ItoN, SaathoffM, et al.Maintanance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol, 2008; 128: 1196–1206.
50.
GilharA, LandauM, AssyB, et al.Melanocyte-associated T-cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol, 2001; 117: 1357–1362.
51.
WadeMS, SinclairRD. Persistent depigmented regrowth after alopecia areata. J Am Acad Dermatol, 2002; 46: 619–620.
52.
CotellessaC, PerisK, CaraccioloE, et al.The use of topical diphencyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol, 2001; 44: 73–76.
53.
RoB. Alopecia areata in Korea. J Dermatol, 1995; 22: 858–864.
54.
ShapiroJ, TanJ, TronV. Diphencyprone and minoxidil in alopecia areata: a clinical and immonopathological evaluation. J Invest Dermatol, 1995; 104: S36.
55.
OrecchiaG, PerfettiL, et al.Photochemotherapy plus squaric acid dibutylester in alopecia areata treatment [letter]. Dermatologica, 1990; 181: 167.
56.
Berth-JonesJ, HutchinsonP. Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone. Clin Exp Dermatol, 1991; 16: 172.
57.
AliA, MartinJM. Hair regrowth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol, 2010; 9: 62–64.
58.
DonovanJ, SalsbergJ. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol, 2012; 148: 1084–1085.
59.
WeiseK, KretzschmarL, JohnSM, HammH. Topical immunotherapy in alopecia areata:anamnestic for the treatment of extensive alopecia areata. J Am Acad Dermatol, 1996; 192: 129–133.
60.
IijimaS, OtsukaF. Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutylester. Arch Dermatol, 1997; 133: 539–540.
61.
ShapiroJ. Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol Clin, 1993; 11: 611–617.
62.
Van der SteenPHM, HappleR. Topical immunotherapy of alopecia areata. Dermatol Clin, 1993; 11: 619–622.
63.
BuckleyDA, Du VivierAW. The therapeutic use of topical contact sensitizers in benign dermatoses. Brit J Dermatol, 2001; 145: 385–405.
64.
HoffmanR, HappleR. Topical immunotherapy in alopecia areata. What, how and why? Dermatol Clin, 1996; 14: 739–744.
65.
GordonPM, AldridgeRD, McVittieE, et al.Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months follow-up. Br J Dermatol, 1996; 13: 869–871.
66.
LinYK, Al-SuwayehSA, LeuYL, et al.Squalene-containing nanostructured lipid carries promote percutaneous absorption and hair follicle targeting for diphencyprone for treating alopecia areata. Pharm Res, 2013; 30: 435–446.
